Low-level Aurora kinase A amplification: CDK4/6 inhibitor resistance biomarker in hormone receptor-positive metastatic breast cancer
NPJ Precision Oncology
Seth A. Wander, Lisa D. Eli, Ezgi Karaesmen Rizvi, Roosheel Sandeep Patel, Emily Schultz, Agnieszka K. Witkiewicz, Georg F. Bischof, Erik S. Knudsen, Karthik V. Giridhar
Abstract
In this large, real-world, translational research cohort of 708 patients in the Tempus database who had hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) metastatic breast cancer with prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) exposure, low-level Aurora kinase A (AURKA) copy-number (CN) gain was common, occurring in 106/708 patients (15.0%). These low-amplification (LA) events impacted RNA expression: patient samples with wild-type AURKA CN had significantly lower median AURKA RNA expression levels than did those with LA or amplified AURKA. Further, LA AURKA CN predicted inferior outcomes on CDK4/6i for patients with HR+, HER2− metastatic breast cancer: real-world progression-free survival was 16.9 months for wild type and 9.3 months for LA AURKA CN (hazard ratio, 1.74; 95% confidence interval, 1.42–2.13; P = 0.0003). These novel results represent the first real-world validation of LA AURKA CN gain as a potential predictor of CDK4/6i resistance.
Related publications